Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A, Balzarotti M, Carniti C, Monfrini C, Chiappella A, Cabras A, Facchetti F, Pennisi M, Rahal D, Monti V, Devizzi L, Miceli R, Cocito F, Farina L, Ricci F, Rossi G, Carlo-Stella C, Corradini P.
Dodero A, et al. Among authors: pennisi m.
Haematologica. 2022 May 1;107(5):1153-1162. doi: 10.3324/haematol.2021.278638.
Haematologica. 2022.
PMID: 34289655
Free PMC article.